David Chang Insider Sell
David Chang, the well informed person, who’s also the EVP - R&D - Chief Medical Off. of Kite Pharma Inc unloaded exactly 7,700 shares of the firm valued by the market at approximately $424,347 USD estimated based on 55.1 USD per share. David is trying to quietly decrease his company’s share, same as he did in the last month. He sold another 7,700 shares worth $423,500 USD. David Chang now indirectly has ownership of 0 shares. He also directly has ownership of 6904 shares. In total he holds a stake of 0.01%.
Kite Pharma Inc Sentiment and Fundamentals
It is difficult to make conclusions about Kite Pharma Inc’s future just from David Chang’s sale because in this filing, the insider also revealed option transactions. In the form, it was reported that David exercised options for 7,700 shares with average price 6.9, worth 53,053. According to nine equity analysts that are covering Kite Pharma Inc’s future, there is an expectation of earnings for each share of $-2.05 for the 2015 year, which gives Kite Pharma Inc a PE ratio of NaN.
We don’t simply rate the stock as a -SELL- because of David’s new stock deal. We also rate it in accordance to our trend system. The share price of Kite Pharma Inc is diving with no signs of trend change after 17.98% move over the last 175 days.
As popular stock speculators including Bruce Kovner shared, best risk-adjusted returns are made through a combination of technical & fundamental analysis. David filled this deal on 02/10/2015. The 4F filing is accessible here at the SEC website.
Institutional Ownership
SEC 13F filings revealed that, 151 institutional investors hold Kite Pharma Inc. The institutional ownership of the firm in the last quarter is high, at 68.17% of the shares outstanding. They increased by 4.83 million the total shares they hold. As of that quarter these investment managers owned 29.82 million shares. A total of 28 funds closed their positions in Kite Pharma Inc and 28 reduced their holdings. There were 40 funds that created new positions and 66 funds that added to their positions.
As reported by SEC’s 13F filings, five institutional holders are confident in the firm as its in their Top 10 stock portfolios.
Wildcat Capital Management Llc is the most bullish institutional investor on Kite Pharma Inc, with ownership of 2.36 million shares as of Q2 2015 for 49.28% of the fund’s portfolio. Rtw Investments Llc is another bullish asset manager possessing 400,000 shares of the company or 7.10% of their stocks portfolio. The stock is also 15.15% of the fund’s AUM. The California-based fund Ecor1 Capital Llc have 5.72% of their stock portfolio invested in the stock for 281,400 shares. Further, Lamond Capital Partners Llc revealed it had acquired a stake worth 6.53% of the fund’s stock portfolio in the company. Guy Shahar’s Dsam Partners Llp was also a big supporter of the publicly listed company, with ownership of 342,188 shares. Kite Pharma Inc is 3.79% of the fund’s stock portfolio.
Kite Pharma NASDAQ:KITE Company Profile
Kite Pharma, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to eradicate cancer cells. The Company does this using its engineered autologous cell therapy (eACT), which is an approach to the treatment of cancer. eACT involves the genetic engineering of T cells to express either chimeric antigen receptors (CARs) or T cell receptors (TCRs). It is conducting a Phase II clinical trial of a TCR-based therapy and multiple Phase I-IIa clinical trials of CAR- and TCR-based therapies. The Company’s lead product candidate KTE-C19, is a CAR-based therapy, for the treatment of refractory diffuse large B cell lymphoma (DLBCL), primary mediastinal B cell lymphoma (PMBCL) and transformed follicular lymphoma (TFL). It is developing a pipeline of eACT-based product candidates for the treatment of advanced solid and hematological malignancies: CD19CAR, KTE-C19CAR and EGFRvlll CAR, among others.
Company Website: Kite Pharma
Today its market worth is: $2.71 billion and it has 47.55 million outstanding shares. The company has 72 employees. Currently there are 70.00% shareholders and the institutional ownership stands at 70.00%. Kite Pharma Inc was incorporated in Delaware on 2009-06-01. The stock closed at $56.990002 yesterday and it had average 2 days volume of 192170 shares. It is down from the 30 days average shares volume of 242787. Kite Pharma Inc has a 52w low of $28.55 and a 52w high of $89.20. The current price is below the 200 days SMA. Kite Pharma Inc last issued its quarterly earnings report on 08/10/2015. The company reported -0.48 EPS for the quarter, missing the consensus estimate of -0.41 by 0.07. The company had a revenue of 4.40 million for 6/30/2015 and 2.88 million for 3/31/2015. Therefore, the revenue was 1.52 million up.
* The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 31 - 2015.
* 25% of the 300 - 000 shares subject to the stock option vested and became exercisable on June 2 - 2015 - and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.
